- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02517411
Physiotherapy in Patients With Stable Chronic Obstructive Pulmonary Disease
Effects of a Physiotherapy Program in Patients With Stable Chronic Obstructive Pulmonary Disease
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Chronic obstructive pulmonary disease (COPD) is one of the leading diseases causing mortality and morbidity, despite advanced pharmacotherapy and therapeutic management. Although COPD primarily affects the lungs, it also implies extrapulmonary manifestations, such as nutritional depletion, skeletal muscle dysfunction, and abnormal respiratory muscles.
Pulmonary rehabilitation is widely used to treat COPD patients and it has been shown that pulmonary rehabilitation should be implemented at all COPD stages, bringing them benefits in terms of improved exercise capacity, symptoms, and quality of life.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Granada, Espanha, 18071
- Department of Physical Therapy
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- COPD diagnosis
- No contraindication of physiotherapy.
- Signed written consent.
- Medical approval for inclusion.
Exclusion Criteria:
- Acute exacerbation in the previous month
- Contraindications of physiotherapy.
- Neurological, orthopedic or heart disease.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Experimental group
COPD patients with stable disease will be recruited and they will receive physiotherapy added to standard care.
|
The treatment will be based on domiciliary physiotherapy program during 8 weeks, twice a week added to standard care.
The duration of the sessions will be 45-60 minutes.
The physiotherapy treatment includes: breathing exercises, electrostimulation in quadriceps with voluntary contraction and exercises with theraband.
This will be a home-based program supervised by a physiotherapist.
Outros nomes:
|
|
Outro: Control group
COPD patients with stable disease will be recruited and they will receive standard care.
|
The standard care of stable COPD is based on long-acting bronchodilators (LABD).
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Changes in Muscle strength
Prazo: Baseline, 8 weeks
|
Quadriceps strength will be assessed with a portable dynamometer.
|
Baseline, 8 weeks
|
|
Changes in Exercise capacity
Prazo: Baseline, 8 weeks
|
Five times sit to stand test (5STS) will be used to assess exercise capacity, 5STS is a simple assessment tool that is feasible in all healthcare settings, and may be a rapid method of assessing changes in exercise capacity in COPD and screening for poor physical functioning individuals.
|
Baseline, 8 weeks
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Changes in Respiratory function
Prazo: Baseline, 8 weeks
|
Spirometry is regarded as the gold standard measure of respiratory function.
Spirometry will be performed according to the American Thoracic Society (ATS) criteria.
|
Baseline, 8 weeks
|
|
Changes in Dyspnea perception
Prazo: Baseline, 8 weeks
|
Dyspnea perception will be assessed with Borg modified scale.
Patients will classify their breathlessness between 0 and 10.
|
Baseline, 8 weeks
|
|
Changes in Quality of life
Prazo: Baseline, 8 weeks
|
EuroQol-5D (EQ-5D) will be used to assess quality of life.
EQ-5D is a generic questionnaire and consists of two parts, the EQ-5D Visual analogue scale (VAS) and the EQ-5D index.
The EQ-5D VAS consists on a vertical rating scale from 0 to 100 (0 = death/worst possible health state and 100 = best possible health state).
The EQ-5D index is a five-item questionnaire (mobility, self-care, usual activity, pain/discomfort and anxiety/depression).
|
Baseline, 8 weeks
|
|
Changes in Fatigue
Prazo: Baseline, 8 weeks
|
Fatigue will be assessed with the Fatigue Severity Scale (FSS).
The FSS is a nine-item instrument designed to assess fatigue as a symptom of a variety of different chronic conditions and disorders.
The scale addresses fatigue's effects on daily functioning, querying its relationship to motivation, physical activity, work, family, and social life, and asking respondents to rate the ease with which they are fatigued and the degree to which the symptom poses a problem for them.
|
Baseline, 8 weeks
|
|
Impact of COPD
Prazo: Baseline, 8 weeks
|
The impact of COPD in patient's life will be evaluated with COPD Assessment Test (CAT) that is a simple instrument to quantify chronic obstructive pulmonary disease (COPD) impact in routine practice.
|
Baseline, 8 weeks
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Quality of life related to respiratory symptoms
Prazo: Baseline
|
Saint George Respiratory Questionnaire (SGRQ) will be also used to evaluate the quality of life of patients in the previous year.
It includes 50 items, divided into three domains: Symptoms, Activity and Impacts.
A score is calculated for each domain and a total score including all items is also obtained.
Low scores indicate better health related quality of life.
|
Baseline
|
|
Peripheral vascular status
Prazo: Baseline
|
Ankle-brachial index will be used to predict the presence or absence of peripheral arterial disease.
|
Baseline
|
|
Physical activity
Prazo: Baseline
|
Modified Baecke Questionnaire will be used to assess the physical activity levels.
It is a frequently used questionnaire to measure habitual physical activity in the elderly.
|
Baseline
|
|
Cognitive status
Prazo: Baseline
|
Cognitive status will be assessed with Montreal Cognitive Assessment test (MoCA) which is a cognitive screening test designed to assist Health Professionals for detection of mild cognitive impairment.
|
Baseline
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- DF0058UG
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .